Pascal Claudepierre
Overview
Explore the profile of Pascal Claudepierre including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
145
Citations
1637
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Maksymowych W, Claudepierre P, de Hooge M, Lambert R, Landewe R, Molto A, et al.
J Rheumatol
. 2024 Feb;
51(5):462-471.
PMID: 38359938
Objective: (1) To compare the capacity to detect sacroiliac joint (SIJ) erosions and baseline-to-week 104 change in erosions between magnetic resonance imaging (MRI) and radiographs in recent-onset axial spondyloarthritis (axSpA);...
12.
Dougados M, Serrand C, Alonso S, Berenbaum F, Claudepierre P, Combe B, et al.
Joint Bone Spine
. 2024 Jan;
91(3):105678.
PMID: 38163581
Objectives: This study aimed to evaluate the 10-year clinical outcome of patients with recent-onset axial spondyloarthritis (axSpA). Methods Study Design: The DESIR cohort is an inception cohort of axSpA patients....
13.
Pina Vegas L, Penso L, Sbidian E, Claudepierre P
RMD Open
. 2023 Dec;
9(4).
PMID: 38114199
Background: Sex differences in phenotype presentation, disease trajectory and treatment response in psoriatic arthritis (PsA) have been reported. Nevertheless, whether classes of targeted therapies differentially affect men and women with...
14.
Pina Vegas L, Claudepierre P
Rheumatology (Oxford)
. 2023 Nov;
63(6):1477-1478.
PMID: 37982745
No abstract available.
15.
Rodrigues-Manica S, Sepriano A, Ramiro S, Landewe R, Claudepierre P, Molto A, et al.
Semin Arthritis Rheum
. 2023 Jun;
61:152225.
PMID: 37263068
Objective: To assess whether the presence of bone marrow edema (BME) leads to the development of structural lesions at the same anatomical location of the sacroiliac joints (SIJ), and to...
16.
Dougados M, Lucas J, Desfleurs E, Claudepierre P, Goupille P, Ruyssen-Witrand A, et al.
RMD Open
. 2023 Mar;
9(1).
PMID: 36921980
Background: Secukinumab efficacy and retention data are emerging in patients with axial spondyloarthritis (axSpA) in real-world settings. However, limited data are available on the predictive factors that affect the retention...
17.
Pina Vegas L, Claudepierre P
Br J Dermatol
. 2023 Jan;
188(3):314-315.
PMID: 36680335
No abstract available.
18.
Pina Vegas L, Hoisnard L, Bastard L, Sbidian E, Claudepierre P
RMD Open
. 2023 Jan;
8(2).
PMID: 36597983
Introduction: Tumour necrosis factor inhibitor (TNFi) agents are most often the first-choice biological treatment for patients with psoriatic arthritis (PsA). When their discontinuation is needed, a switch to another TNFi...
19.
Pina Vegas L, Claudepierre P
Rheumatology (Oxford)
. 2022 Sep;
62(4):1362-1363.
PMID: 36083026
No abstract available.
20.
Beauvais C, Pereira B, Pham T, Sordet C, Claudepierre P, Fayet F, et al.
J Rheumatol
. 2022 Jul;
50(1):56-65.
PMID: 35840152
Objective: To develop and validate a patient knowledge questionnaire regarding axial spondyloarthritis (axSpA). Methods: Knowledge considered essential for patients with axSpA was identified through Delphi rounds among rheumatologists, healthcare professionals...